ArticleJournal of thoracic disease2025

Efficacy and safety of anlotinib combined with immunotherapy as first-line treatment in elderly patients with advanced non-small cell lung cancer.

Xiqing Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.